Table 2

Clinical features at diagnosis of patients with myopathy related to systemic sclerosis

Type

Antibody

At baseline

At diagnosis

Aldolase

(0 to 7 U/L)

AST

(0 to 32 U/L)

ALT

(0 to 32 U/L)

CK

(0 to 160 U/L)

8MMT

(0 to 80)

Aldolase

(0 to 7 U/L)

AST

(0 to 32 U/L)

ALT

(0 to 32 U/L)

CK

(0 to 160 U/L)

EMG

Thigh muscle RMI

Muscular biopsy


1

dSSc

ATA

16

38

12

34

66

19

172

49

800

+

-

+

2

dSSc

ATA

9

35

20

11

60

9.7

58

28

234

+

-

+

3

lSSc

ACA

15.8

36

24

25

64

40

86

32

100

-

+

+

4

lSSc

ATA

23.5

25

31

31

55

9.3

53

25

364

+

+

+

5

lSSc

ACA

29

55

54

18

68

37.2

962

22

1,180

+

+

+

6

dSSc

ATA

PM-Scl

9.3

56

29

36

66

22.4

122

99

254

+

+

+

7

dSSc

ATA

U3-RNP

16.2

54

14

21

68

17.8

109

52

271

+

+

+

8

lSSc

ACA

13.6

50

16

19

64

24.8

173

96

40

+

+

ND

9

dSSc

0

11.6

14

15

14

69

9.1

57

20

28

+

+

ND


+ means the presence of abnormalities described as criteria of myositis according to the EMNC (5); ACA, Anti-centromere antibodiy; ATA, Anti-topoisomerase I antibody; CK, creatine kinase; dSSc, diffuse form of systemic sclerosis; all patients had antinuclear antibody positive; EMG, electromyography; lSSc, limited cutaneous form of systemic sclerosis; ND, not done; PM-Scl, anti- polymyositis-scleroderma antibody; RMI, resonance magnetic imaging; U3-RNP, Anti U3-RNP antibody; Yrs, years

Tolédano et al. Arthritis Research & Therapy 2012 14:R152   doi:10.1186/ar3888

Open Data